Talphera, Inc.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Vincent J. Angotti
- Full Time Employees
- 13
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Address
- 1850 Gateway Drive San Mateo CA United States of America 94404
- IPO Date
- Feb 11, 2011
- CIK
- 0001427925
- Website
- talphera.com
- Similar Companies
- Business
- Talphera, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings. Its core product portfolio includes injectable ephedrine and phenylephrine prefilled syringes, marketed under the brand names Fedsyra™ and PFS-02 respectively, developed in partnership with France-based Laboratoire Aguettant to enhance safety and convenience in perioperative and acute-care settings. Talphera is also advancing Niyad™ (nafamostat mesylate), an anticoagulant in late-stage clinical development for use in continuous renal replacement therapy (CRRT) for critically ill patients, aiming for FDA PMA approval anticipated in the second half of 2026. The company’s products target hospital and acute care providers in North America and other markets, focusing on improving patient outcomes with innovative delivery formats and novel therapies. Talphera was founded in 2005 and is headquartered in Redwood City, California. The company underwent a strategic shift in 2023, renaming from AcelRx Pharmaceuticals to Talphera to reflect its broadened focus beyond acute pain products to a wider portfolio for medically supervised care. Recently, Talphera closed a $17 million financing round led by CorMedix, which includes rights for CorMedix to negotiate an acquisition following positive NEPHRO study results related to its nafamostat candidate. This financing supports the advancement of Niyad™ through to regulatory approval and commercialization. Talphera continues to expand clinical trial sites for its NEPHRO study with the goal of completing enrollment by the end of 2025. The company maintains a strong cash position and operational focus on delivering innovative pharmaceutical solutions that optimize clinical outcomes in critical care settings.
Talphera, Inc. (TLPH) Q1 2026 Earnings Call Transcript
Talphera Announces First Quarter 2026 Financial Results and Provides Corporate Update
Talphera to Host First Quarter Financial Results and Corporate Update Call and Webcast on Wednesday, May 13, 2026
Talphera Announces Two Abstracts Accepted for Presentation at AKI & CRRT 2026
Talphera Q4 Earnings Call Highlights
Talphera, Inc. (TLPH) Analyst/Investor Day Transcript
Talphera Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
Talphera to Host Virtual Investor & Analyst Event to Discuss Niyad® for Use in Continuous Renal Replacement Therapy (CRRT), on March 23, 2026
Talphera Announces 50% Enrollment Milestone in Ongoing NEPHRO-CRRT Registrational Trial
Talphera (NASDAQ:TLPH) Insider Purchases $28,350.00 in Stock
Insider Buying: Talphera (NASDAQ:TLPH) Insider Acquires $28,350.00 in Stock
Insider Buying: Talphera (NASDAQ:TLPH) CFO Buys $36,450.00 in Stock
Talphera (NASDAQ:TLPH) Shares Down 0.3% – Here’s What Happened
Talphera (NASDAQ:TLPH) Stock Price Down 2.7% – Here’s Why
Talphera, Inc. (TLPH) Q3 2025 Earnings Call Transcript
Talphera Announces Third Quarter 2025 Financial Results and Provides Corporate Update
Talphera to Host Third Quarter Financial Results and Corporate Update Call and Webcast on Wednesday, November 12, 2025
Talphera, Inc. (NASDAQ:TLPH) Given Consensus Rating of “Buy” by Brokerages
Talphera Announces the Appointment of Joe Todisco to Board of Directors
CorMedix Announces Strategic Minority Investment in Talphera